Endocrine Abstracts

Background: MEN -1 is caused by a pathogenic variant in the tumour suppressor gene leading to a tumour development. Registry data quotes an increased risk in breast cancer and thromboembolic disease. Recent best practice guidance does not currently recommend breast cancer screening in this group. The Dutch registry data reports invasive breast cancer in 12 of 190 females (with MEN-1) with a relative risk of 2.83 and approximately 6 % developing breast cancer. With respect to VTE, the lifetime risk has been has been estimated to be 2 fold higher with a pooled prevalence of 11.1% in MEN-1.

Objectives: To review our practice: recording: demographic data, genetic MEN 1 diagnosis, incidence of breast cancer and VTE.

Methodology: Interrogation of the Sheffield NET database was performed filtering for ‘multiple endocrine neoplasia’ and MEN 1 patients selected. Evidence of breast cancer and VTE was then reviewed.

Results: 164 patients were listed as having a form of multiple endocrine neoplasia. 67 were confirmed to be gene positive. 8% of all patients underwent triple assessment (examination, mammography and biopsy) for breast cancer. 3% with MEN-1 were found to have a diagnosis of breast cancer (5 patients). A total of 13 patients (8% of total) had a thromboembolic event, where 9 were MEN-1 gene positive, 3 of these patients developed both a DVT and PE. 2 patients with the MEN-1 gene developed both breast cancer and TED.

Conclusion: In this limited dataset Sheffield NET Centre has a small proportion of patients who presented with breast cancer or VTE. Clinicians should carefully review any family history of breast cancer and advise patients on self-examination. Looking forward a worldwide study is needed to inform if earlier breast screening is warranted and useful. In the future AI may prove to be useful in assessment of MEN surveillance interval imaging.